- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT04438239
Rehabilitation Needs After COVID-19 Hospital Treatment (REACT)
Rehabilitation Needs After COVID-19 Hospital Treatment (REACT): an Observational Study
The onset of Coronavirus Disease 2019 (COVID-19) in the first months of 2020 had a huge impact on Italian population and Healthcare System, with more than 150.000 total confirmed cases1. SARS-CoV-2 is a highly contagious new virus, causing an influenza like illness and respiratory tract infection demonstrating fever (89%), cough (68%), fatigue (38%), sputum production (34%) and/or shortness of breath (19%).
The aim of this observational study is to detect symptoms, disabilities, participation and the lived experience of the disease in individuals affected by COVID-19 two months after the hospital discharge.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
The onset of Coronavirus Disease 2019 (COVID-19) in the first months of 2020 had a huge impact on Italian population and Healthcare System, with more than 150.000 total confirmed cases. SARS-CoV-2 is a highly contagious new virus, causing an influenza like illness and respiratory tract infection demonstrating fever (89%), cough (68%), fatigue (38%), sputum production (34%) and/or shortness of breath (19%). The spectrum of disease severity ranges from an asymptomatic infection or mild upper respiratory tract illness (80% of cases), to 15% of cases with severe infection with fever, cough, fatigue and shortness of breath, requiring oxygen, and 5% are severe viral pneumonia with respiratory failure requiring ventilation and life support and/or death. At present, clinicians do not know the real impact of Coronavirus Disease on patients' performances, functional status and QoL. Patients admitted to hospital experience fever, cough, dyspnea, muscle soreness and/or acute respiratory distress syndrome but healthcare professionals observe also anxiety, depression and important functional limitations during hospital stay. This situation is expected to have a significant negative impact in the short term, mainly for patients affected by other medical conditions and it may lead to deconditioning, fatigue, isolation, poor functional status and QoL.
In the first months after COVID-19 outbreak, researchers focused their studies on infection epidemiology, transmission, COVID-19 diagnosis and medical treatments. As the epidemic progresses, a large part of patients is expected to come out of the acute phase, and they may need adequate rehabilitation to face functional limitations and return to previous levels of participation.
To date, the very few studies published on the rehabilitation of positive and symptomatic patients with COVID-19 focused on pulmonary rehabilitation guidelines or on implications for rehabilitation services. To our knowledge, no clinical trial on rehabilitation intervention for patients after COVID-19 is ongoing. Our research group set up an observational study to detect patients' rehabilitation needs after COVID-19, collecting data on symptoms, impairments, functional abilities and participations to social life in the first months after hospital discharge.
The aim of this observational study is to detect symptoms, disabilities, participation and the lived experience of the disease in individuals affected by COVID-19 two months after the hospital discharge.
Studientyp
Einschreibung (Tatsächlich)
Kontakte und Standorte
Studienorte
-
-
-
Reggio Emilia, Italien, 42123
- Azienda USL-IRCCS S.Maria Nuova Hospital
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Beschreibung
Inclusion Criteria:
- age>18,
- positive at COVID-19
- manifesting symptoms that required hospitalization, that is history of fever or pneumonia or other symptoms COVID-19 related.
Exclusion Criteria:
- asymptomatic individuals COVID-19 positive that were hospitalized for reasons other than COVID-19;
- dementia;
- psychiatric disorders
- other diseases preventing people to participate to the rehabilitation assessments provided by this protocol;
- acute or post-acute clinical conditions causing disability itself (e.g.: major neurological disease, such as recent stroke, TBI, etc., or recent surgical intervention, or heart failure, etc.),
- previous complete dependence in ADLs .
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Beobachtungsmodelle: Sonstiges
- Zeitperspektiven: Interessent
Kohorten und Interventionen
Gruppe / Kohorte |
Intervention / Behandlung |
|---|---|
|
Covid-19 discharged
Patients affected by COVID-19 and discharged from hospital wards of the Azienda USL- IRCCS Of Reggio Emilia (Italy).
|
none, this study is observational
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
number of participants with considerable dyspnea: Medical Research Council (MRC, 0-4, lower score better outcome)
Zeitfenster: 2-months after hospital discharge
|
Dyspnea will be measured with Medical Research Council (MRC), minimum value 0-maximum value 4, lower value= better outcome
|
2-months after hospital discharge
|
|
number of participants with fatigue
Zeitfenster: 2-months after hospital discharge
|
Fatigue will be assessed with Fatigue Severity Scale (FSS), minimum value 9-maximum value 63, lower value=better outcome
|
2-months after hospital discharge
|
|
number of participants with anxiety
Zeitfenster: 2-months after hospital discharge
|
anxiety will be assessed with Hospital Anxiety and Depression Scale (HADS), subscale 'Anxiety', minimum value 0-maximum value 24, lower score=better outcome, cut-off for clinically significant anxiety score>7
|
2-months after hospital discharge
|
|
number of participants with depression
Zeitfenster: 2-months after hospital discharge
|
depression will be assessed with Hospital Anxiety and Depression Scale (HADS), subscale 'Depression', minimum value 0-maximum value 24, lower score=better outcome, cut-off for clinically significant depression score>7
|
2-months after hospital discharge
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
level of independence in B-ADL
Zeitfenster: 2-months after hospital discharge
|
independence or disability will be assessed with Barthel Index (BI), minimum score 0- maximum score 100, higher score=better outcome
|
2-months after hospital discharge
|
|
level of participation in social
Zeitfenster: 2-months after hospital discharge
|
reintegration into normal social activities (e.g.
recreation, movement in the community, and interaction in family or other relationships) will be assessed with Reintegration to Normal Living Index (RNLI), minimum score 0-maximum score 100, higher score=better outcome
|
2-months after hospital discharge
|
|
description of qualitative data about patients' experience
Zeitfenster: 2-months after hospital discharge
|
open ended questions will be recorded, transcribed verbatim and analyzed (two questions addressed to symptoms and limitations in activities that patients may have experienced during hospitalization or after discharge)
|
2-months after hospital discharge
|
Mitarbeiter und Ermittler
Ermittler
- Hauptermittler: Stefania Fugazzaro, MD, Azienda USL - IRCCS of Reggio Emilia (Italy)
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Boldrini P, Bernetti A, Fiore P; SIMFER Executive Committee, SIMFER Committee for International Affairs. Impact of COVID-19 outbreak on rehabilitation services and Physical and Rehabilitation Medicine physicians' activities in Italy. An official document of the Italian PRM Society (SIMFER). Eur J Phys Rehabil Med. 2020 Jun;56(3):316-318. doi: 10.23736/S1973-9087.20.06256-5. Epub 2020 Mar 16. No abstract available.
- Fugazzaro S, Denti M, Mainini C, Accogli MA, Bedogni G, Ghizzoni D, Bertolini A, Esseroukh O, Gualdi C, Schiavi M, Braglia L, Costi S. Sex differences and rehabilitation needs after hospital discharge for COVID-19: an Italian cross-sectional study. BMJ Open. 2022 May 18;12(5):e055308. doi: 10.1136/bmjopen-2021-055308.
- Schiavi M, Fugazzaro S, Bertolini A, Denti M, Mainini C, Accogli MA, Bedogni G, Ghizzoni D, Esseroukh O, Gualdi C, Costi S. "Like before, but not exactly": the Qualy-REACT qualitative inquiry into the lived experience of long COVID. BMC Public Health. 2022 Mar 28;22(1):599. doi: 10.1186/s12889-022-13035-w.
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 428/2020/OSS/AUSLRE
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Produkt, das in den USA hergestellt und aus den USA exportiert wird
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Covid-19
-
PfizerAktiv, nicht rekrutierendCOVID-19 | Coronavirus-Krankheit 2019 (COVID-19) | Covid-19 Infektion | Covid-19 Impfungen | SARS-CoV-2-Infektion, COVID19 | COVID-19-Impfung | SARS-CoV-2-Infektion, COVID-19 | COVID-19 (Coronavirus-Krankheit 2019) | COVID-19 SARS-CoV-2-InfektionVereinigte Staaten
-
Shanghai Public Health Clinical CenterNoch keine Rekrutierung
-
Duke UniversityNational Institute on Minority Health and Health Disparities (NIMHD)Abgeschlossen
-
Eggensberger OHGBavarian Health and Food Safety Authority (LGL)RekrutierungZustand nach COVID-19 | Nach COVID-19 | Post-COVID-19-Syndrom | Langes COVID-19-Syndrom | Zustand nach COVID-19 (PCC)Deutschland
-
PfizerRekrutierungErkrankungen der Atemwege | COVID-19 | Lungenentzündung | Lungenkrankheit | Coronavirus Krankheit 2019 | Coronavirus-Krankheit 2019 (COVID-19) | Covid-19 Infektion | Infektionen der oberen Atemwege | Infektion der Atemwege | COVID-19 (Coronavirus-Krankheit 2019) | COVID-19 SARS-CoV-2-InfektionBelgien
-
University of Missouri, Kansas CityNational Institute on Minority Health and Health Disparities (NIMHD)Aktiv, nicht rekrutierendCovid-19-TestverhaltenVereinigte Staaten
-
ModeX Therapeutics, An OPKO Health CompanyRekrutierungCOVID 19 | COVID-19 (Prävention)Vereinigte Staaten
-
Lawson Research Institute of St. Joseph'sCanadian Institutes of Health Research (CIHR); Western University, CanadaRekrutierungErmüdung | Post-COVID-19-Syndrom | Zustand nach COVID-19 | Post-COVID-Syndrom | Lange COVID-19 | Lang-COVID | Post-COVID-ZustandKanada
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios...AbgeschlossenPostakute Folgen von COVID-19 | Zustand nach COVID-19 | Lang-COVID | Chronisches COVID-19-SyndromItalien
-
RSUP PersahabatanAbgeschlossenPost-COVID-19-Syndrom | Langes COVID-19-Syndrom | Post-COVID-Syndrom Long CovidIndonesien
Klinische Studien zur none, this study is observational
-
Royal Marsden NHS Foundation TrustFondazione IRCCS Istituto Nazionale dei Tumori, Milano; Cancer Research UK; University... und andere MitarbeiterRekrutierungSarkom | Weichgewebe-Sarkom Erwachsener | Liposarkom | Angiosarkom | Weichteilsarkom des Gliedes | Retroperitoneales Sarkom | Liposarkom, entdifferenziert | Leiomyosarkom (LMS) | Weichteilsarkom des Rumpfes und der Extremitäten | Weichteilsarkom (STS) | Sarkom, Leiomyo-, Erwachsene | Sarkom, Synovial, ErwachseneVereinigtes Königreich
-
AstraZenecaAbgeschlossenBrustkrebs | Onkologie | EpidemiologieAlgerien